DK1398038T3 - Lægemidler med botulinustoxin - Google Patents

Lægemidler med botulinustoxin

Info

Publication number: DK1398038T3
Authority: DK; Denmark
Prior art keywords: botulinum toxin; toxin drugs; drugs; botulinum; toxin
Prior art date: 2000-02-08

Application number

DK03025104T

Other languages

English (en)

Other versions

DK1398038T4 (da

Inventor

Terrence J Hunt

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-08

Filing date

2001-02-05

Publication date

2007-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23988236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1398038(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-02-05 Application filed by Allergan Inc filed Critical Allergan Inc

2007-04-02 Publication of DK1398038T3 publication Critical patent/DK1398038T3/da

2011-03-28 Application granted granted Critical

2011-03-28 Publication of DK1398038T4 publication Critical patent/DK1398038T4/da

Links

108030001720 Bontoxilysin Proteins 0.000 title 1
229940053031 botulinum toxin Drugs 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)

DK03025104.5T 2000-02-08 2001-02-05 Lægemidler med botulinustoxin DK1398038T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50014700A	2000-02-08	2000-02-08
PCT/US2001/003641 WO2001058472A2 (en)	2000-02-08	2001-02-05	Botulinum toxin pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
DK1398038T3 true DK1398038T3 (da)	2007-04-02
DK1398038T4 DK1398038T4 (da)	2011-03-28

Family

ID=23988236

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK03025104.5T DK1398038T4 (da)	2000-02-08	2001-02-05	Lægemidler med botulinustoxin
DK04029089.2T DK1514556T3 (da)	2000-02-08	2001-02-05	Farmaceutiske sammensætninger med botulinustoxin
DK01905436T DK1253932T3 (da)	2000-02-08	2001-02-05	Lægemidler med botulinustoxin

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK04029089.2T DK1514556T3 (da)	2000-02-08	2001-02-05	Farmaceutiske sammensætninger med botulinustoxin
DK01905436T DK1253932T3 (da)	2000-02-08	2001-02-05	Lægemidler med botulinustoxin

Country Status (19)

Country	Link
US (2)	US20020064536A1 (da)
EP (4)	EP1398038B2 (da)
JP (7)	JP2003522154A (da)
KR (3)	KR100753765B1 (da)
CN (2)	CN1258379C (da)
AR (1)	AR027391A1 (da)
AT (2)	ATE519494T1 (da)
AU (2)	AU3331501A (da)
BR (1)	BR0108173A (da)
CA (3)	CA2478621C (da)
CY (1)	CY1108007T1 (da)
DE (2)	DE60125986T3 (da)
DK (3)	DK1398038T4 (da)
ES (3)	ES2237551T3 (da)
MX (1)	MXPA02007519A (da)
NZ (2)	NZ530779A (da)
PT (3)	PT1253932E (da)
TW (2)	TWI317283B (da)
WO (1)	WO2001058472A2 (da)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
CA2478621C (en) *	2000-02-08	2006-11-21	Allergan, Inc.	Botulinum toxin pharmaceutical compositions
US7780967B2 (en) *	2000-02-08	2010-08-24	Allergan, Inc.	Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) *	2000-02-08	2014-01-21	Allergan, Inc.	Clostridial toxin pharmaceutical composition containing a gelatin fragment
DE10035156A1 (de) *	2000-07-19	2002-02-07	Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh	Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6423319B1 (en) *	2000-10-04	2002-07-23	Allergan Sales, Inc.	Methods for treating muscle injuries
DE10149030A1 (de) *	2001-10-05	2003-04-10	Viscum Ag	Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7140371B2 (en) *	2002-03-14	2006-11-28	Allergan, Inc.	Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
AU2003221050A1 (en) *	2002-03-29	2003-10-13	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Remedy for hypermyotonia
US7459164B2 (en)	2002-05-28	2008-12-02	Botulinum Toxin Research Associates, Inc.	Composition for therapeutic and cosmetic botulinum toxin
US7691394B2 (en)	2002-05-28	2010-04-06	Botulinum Toxin Research Associates, Inc.	High-potency botulinum toxin formulations
US7238357B2 (en)	2002-11-05	2007-07-03	Allergan, Inc.	Methods for treating ulcers and gastroesophageal reflux disease
EP1594523B1 (en) *	2002-12-20	2009-03-25	Botulinum Toxin Research Associates, Inc.	Pharmaceutical compositions comprising botulinum toxin and human serum albumin
KR20060002922A (ko) *	2003-03-31	2006-01-09	알자 코포레이션	비수성 단일 상 비히클 및 이러한 비히클을 이용한 제형
US7220422B2 (en) *	2003-05-20	2007-05-22	Allergan, Inc.	Methods and compositions for treating eye disorders
FR2855177B1 (fr) *	2003-05-23	2005-07-08	Raymond Robert	Composition contenant des acides nucleiques lyophilises en presence de collagene et de disaccharides
US7160699B2 (en)	2003-09-25	2007-01-09	Allergan, Inc.	Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7452697B2 (en)	2003-09-25	2008-11-18	Allergan, Inc.	Chromatographic method and system for purifying a botulinum toxin
US7148041B2 (en)	2003-09-25	2006-12-12	Allergan, Inc.	Animal product free media and processes for obtaining a botulinum toxin
US9078892B2 (en) *	2004-02-26	2015-07-14	Allergan, Inc.	Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) *	2004-02-26	2005-09-01	Allergan, Inc.	Methods for treating headache
US20100266638A1 (en)	2004-02-26	2010-10-21	Allergan, Inc.	Headache treatment method
US7691381B2 (en)	2004-04-15	2010-04-06	Allergan, Inc.	Stabilized biodegradable neurotoxin implants
RU2255761C1 (ru) *	2004-07-01	2005-07-10	Общество с ограниченной ответственностью "Токсины и сопутствующие продукты"	Препарат для лечения мышечных дистоний из токсина культуры clostridium botulinum и способ его получения
GB2416122A (en)	2004-07-12	2006-01-18	Ipsen Ltd	Botulinum neurotoxin composition
ES2479515T3 (es)	2004-07-26	2014-07-24	Merz Pharma Gmbh & Co. Kgaa	Composición terapéutica con una neurotoxina botulínica
WO2006013370A1 (en)	2004-08-04	2006-02-09	Ipsen Limited	Pharmaceutical composition containing botulinum neurotoxin a2
ES2627627T3 (es)	2004-08-04	2017-07-28	Ipsen Biopharm Limited	Composición farmacéutica que contiene neurotoxina botulínica A2
US8192979B2 (en)	2005-01-03	2012-06-05	Botulinum Toxin Research Associates, Inc.	Compositions, methods and devices for preparing less painful Botulinum toxin formulations
US7838011B2 (en)	2005-02-14	2010-11-23	Pankaj Modi	Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en)	2005-02-14	2010-06-01	Dpm Therapeutics Corp.	Stabilized compositions for topical administration and methods of making same
DK1853623T3 (da) *	2005-03-03	2013-07-15	Allergan Inc	Dyreprodukt-frit system og fremgangsmåde til oprensning af et botulinumtoksin
EP1861112A4 (en) *	2005-03-03	2009-07-22	Revance Therapeutics Inc	COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINES
US8926991B2 (en) *	2005-06-14	2015-01-06	Botulinum Toxin Research Associates, Inc.	Botulinum toxin and the treatment of primary disorders of mood and affect
US20230390368A1 (en) *	2005-06-27	2023-12-07	Revance Therapeutics, Inc.	Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s)
US20070027105A1 (en)	2005-07-26	2007-02-01	Alza Corporation	Peroxide removal from drug delivery vehicle
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
FR2889936B1 (fr)	2005-09-01	2007-12-21	Sod Conseils Rech Applic	Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7744904B1 (en) *	2005-09-26	2010-06-29	B.B. Scientific L.L.C.	Stabilization of Clostridium botulinum neurotoxin complex
US8137677B2 (en)	2005-10-06	2012-03-20	Allergan, Inc.	Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) *	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
AU2013202329B2 (en) *	2005-10-06	2016-04-14	Allergan, Inc.	Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007044809A2 (en) *	2005-10-11	2007-04-19	Botulinum Toxin Research Associates, Inc.	Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
CN100384993C (zh) *	2005-11-02	2008-04-30	浙江大学	提高地衣芽孢杆菌zjuel31410弹性蛋白酶稳定性的方法
FR2896693B1 (fr) *	2006-01-27	2008-03-14	Sod Conseils Rech Applic	Composition comprenant plusieurs toxines botuliques
DE102006019447A1 (de) *	2006-04-24	2007-10-25	Dressler, Dirk, Dr.	Markierung von Botulinum Toxin
WO2007139553A1 (en)	2006-05-31	2007-12-06	Genzyme Corporation	Use of polysaccharides for promotion of enzymatic activity
FR2902341B1 (fr) *	2006-06-16	2011-02-25	Scras	Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr)	2006-10-27	2012-12-28	Scras	Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr)	2006-12-22	2013-04-26	Scras	Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CN102988995A (zh) *	2006-12-29	2013-03-27	雷文斯治疗公司	用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
GB0705245D0 (en)	2007-03-19	2007-04-25	Stabilitech Ltd	Stable biological products
AU2008261261B2 (en) *	2007-06-13	2013-06-27	Csl Behring Gmbh	Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
KR101087017B1 (ko) *	2007-07-10	2011-12-09	(주)메디톡스	보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물
US7473429B1 (en) *	2007-07-27	2009-01-06	Renfroe J Ben	Method for treatment of laminitis in animals
JP2009132686A (ja) *	2007-10-26	2009-06-18	Okayama Univ	ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法
EP2072039A1 (en)	2007-12-21	2009-06-24	Merz Pharma GmbH & Co.KGaA	Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
EP2072057A1 (en)	2007-12-21	2009-06-24	Merz Pharma GmbH & Co.KGaA	Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
US9107815B2 (en)	2008-02-22	2015-08-18	Allergan, Inc.	Sustained release poloxamer containing pharmaceutical compositions
FR2930447B1 (fr)	2008-04-25	2010-07-30	Sod Conseils Rech Applic	Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
WO2010016901A1 (en) *	2008-08-05	2010-02-11	Solstice Neurosciences, Inc.	Compositions of activated botulinum holotoxin type b (150 kd)
US20100034853A1 (en) *	2008-08-05	2010-02-11	Solstice Neurosciences, Inc.	Compositions of activated botulinum toxin type B
US20100112005A1 (en) *	2008-11-03	2010-05-06	Solstice Neurosciences, Inc.	Compositions of activated botulinum toxin type B
WO2010051038A1 (en) *	2008-11-03	2010-05-06	Solstice Neurosciences, Inc.	Compositions of activated botulinum holotoxin type b (150 kd)
EP2364168A1 (en)	2008-12-04	2011-09-14	Botulinum Toxin Research Associates, Inc.	Extended length botulinum toxin formulation for human or mammalian use
RU2535003C2 (ru) *	2008-12-10	2014-12-10	Аллерган, Инк.	Фармацевтические композиции токсина клостридий
JP5866202B2 (ja)	2008-12-31	2016-02-17	ルバンスセラピュティックスインク．ＲｅｖａｎｃｅＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	注射用ボツリヌス毒素製剤
US20100184685A1 (en) *	2009-01-19	2010-07-22	Zavala Jr Gerardo	Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
EP2248518B1 (en)	2009-04-17	2013-01-16	Merz Pharma GmbH & Co. KGaA	Formulation for stabilizing proteins, peptides or mixtures thereof.
CN102869373B (zh)	2009-06-25	2017-05-10	雷文斯治疗公司	不含白蛋白的肉毒杆菌毒素制剂
US8129139B2 (en)	2009-07-13	2012-03-06	Allergan, Inc.	Process for obtaining botulinum neurotoxin
CA2792771A1 (en) *	2010-03-12	2011-09-15	Surmodics, Inc.	Injectable drug delivery system
JP5769379B2 (ja) *	2010-03-17	2015-08-26	グンゼ株式会社	Ｄａｎｃｅタンパク質溶液
JP2013545504A (ja) *	2010-10-06	2013-12-26	アラーガン、インコーポレイテッド	ボツリヌス毒素の貯蔵およびその後の取り扱いのためのシステム
WO2012048854A2 (en)	2010-10-12	2012-04-19	Merz Pharma Gmbh & Co. Kgaa	Formulation suitable for stabilizing proteins, which is free of mammalian excipients
BR112013025256B1 (pt)	2011-03-31	2022-01-18	Medy-Tox Inc	Preparação liofilizada farmacêutica
KR101135486B1 (ko)	2011-05-25	2012-04-13	함종욱	보툴리눔 에이형 독소의 액상제품
US9393291B2 (en)	2012-04-12	2016-07-19	Botulinum Toxin Research Associates, Inc.	Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9901627B2 (en)	2014-07-18	2018-02-27	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en)	2014-07-18	2022-11-01	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN104189891B (zh) *	2014-08-15	2016-03-30	北京四环生物制药有限公司	一种不含人血清蛋白的重组人促红素制剂
MX380066B (es) *	2014-12-23	2025-03-11	Merz Pharma Gmbh & Co Kgaa	Recipiente precargado con toxina botulinica.
US10406290B2 (en)	2015-02-03	2019-09-10	Merz Pharma Gmbh & Co. Kgaa	Botulinum toxin prefilled plastic syringe
WO2017075468A1 (en)	2015-10-29	2017-05-04	Revance Therapeutics, Inc.	Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
WO2017188618A1 (en) *	2016-04-26	2017-11-02	Korea Prime Pharm Co., Ltd.	A novel composition comprising botulinum toxin
TWI777955B (zh)	2016-05-27	2022-09-21	英商益普生生物製藥有限公司	神經毒素調配物
WO2018038585A1 (ko) *	2016-08-26	2018-03-01	주식회사 에이비바이오	보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
WO2018038301A1 (en) *	2016-08-26	2018-03-01	Hugel Inc.	Stabilized liquid formulation of botulinum toxin and preparation method thereof
JP7217700B2 (ja)	2016-09-13	2023-02-03	アラーガン、インコーポレイテッド	安定化非タンパク質クロストリジウム毒素組成物
EP3675900A4 (en)	2017-08-28	2021-05-05	Revance Therapeutics, Inc.	Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
KR20190038292A (ko) *	2017-09-29	2019-04-08	한국프라임제약주식회사	효능 지속시간이 연장된 보툴리눔 독소 조성물
CA3082264C (en) *	2017-11-17	2024-04-16	Swedish Orphan Biovitrum Ab (Publ)	Syringe assembly with ion-exchange material
KR102063475B1 (ko) *	2018-02-22	2020-01-09	주식회사 에이비바이오	보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
KR102259423B1 (ko) *	2018-11-30	2021-06-02	주식회사 휴온스바이오파마	보툴리눔 독소의 안정화 액상 조성물
WO2020111852A1 (ko)	2018-11-30	2020-06-04	주식회사 휴온스글로벌	보툴리눔 독소의 안정화 액상 조성물
WO2021146215A1 (en)	2020-01-13	2021-07-22	Durect Corporation	Sustained release drug delivery systems with reduced impurities and related methods
BR112022020327A2 (pt) *	2020-04-08	2022-12-13	Medytox Inc	Formulação de seringa pré-carregada com toxina botulínica
KR102404217B1 (ko) *	2020-04-08	2022-06-02	(주)메디톡스	토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형
CN111675754A (zh) *	2020-05-19	2020-09-18	四川一埃科技有限公司	一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法
KR20250003215A (ko)	2023-06-30	2025-01-07	주식회사 휴온스바이오파마	폴리솔베이트 20 및 세린을 포함하는 보툴리눔 독소의 안정화 액상 조성물
WO2025059665A1 (en)	2023-09-15	2025-03-20	Revance Therapeutics, Inc.	Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en)	2023-09-19	2025-03-27	Revance Therapeutics, Inc.	Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
CN118697853B (zh) *	2024-06-27	2025-05-02	河北封章生物科技有限公司	一种稳定性提高的肉毒素制剂

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3269912A (en) *	1963-04-08	1966-08-30	Boehringer & Soehne Gmbh	Aluminum oxide depot vaccines
US3758382A (en) *	1968-07-26	1973-09-11	Us Navy	Ve agent process of freezing blood using a hydroxyalkyl starch as cryoprotecti
GB1514720A (en) *	1974-10-07	1978-06-21	Secr Defence	Preparation of hydroxyethyl starch
DE2457047C3 (de) *	1974-12-03	1979-10-31	Behringwerke Ag, 3550 Marburg	Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe
NZ199722A (en) *	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4391801A (en) *	1981-10-29	1983-07-05	Cutter Laboratories, Inc.	Plasma protein fraction substantially free of acetate ions
JPS5959625A (ja) *	1982-09-28	1984-04-05	Dainippon Pharmaceut Co Ltd	ガン壊死因子を安定化する方法
US4457916A (en) *	1982-08-31	1984-07-03	Asahi Kasei Kogyo Kabushiki Kaisha	Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
HU188847B (en) *	1983-02-22	1986-05-28	Human Oltoanyagtermeloe Es Kutato Intezet,Hu	Process for producing liophylized combined vaccines
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
EP0150067A3 (en) *	1984-01-23	1986-12-30	Takeda Chemical Industries, Ltd.	Stable composition of gamma-interferon
JPS61161222A (ja) *	1985-01-09	1986-07-21	Takeda Chem Ind Ltd	γ型インタ−フエロンフラグメントの組成物
JPS60258125A (ja) *	1984-06-06	1985-12-20	Hayashibara Biochem Lab Inc	蛋白性生理活性物質を含有する水溶性乾燥物
US4597966A (en) *	1985-01-09	1986-07-01	Ortho Diagnostic Systems, Inc.	Histidine stabilized immunoglobulin and method of preparation
JPS61194034A (ja) *	1985-02-25	1986-08-28	Teijin Ltd	経鼻投与用粉末状組成物
US4962091A (en) *	1986-05-23	1990-10-09	Syntex (U.S.A.) Inc.	Controlled release of macromolecular polypeptides
DE3621828A1 (de) *	1986-06-28	1988-01-14	Biotest Pharma Gmbh	Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
JPH0696536B2 (ja) *	1988-02-26	1994-11-30	佐藤製薬株式会社	制酸剤含有内用懸濁液
JP2849632B2 (ja) *	1988-04-08	1999-01-20	社団法人北里研究所	ワクチン製剤
FR2630115B1 (fr) *	1988-04-14	1994-10-28	Merieux Inst	Procede de stabilisation des solutions d'albumine humaine et solution obtenue
FR2649991B2 (fr) †	1988-08-05	1994-03-04	Rhone Poulenc Sante	Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5997856A (en) *	1988-10-05	1999-12-07	Chiron Corporation	Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5919665A (en) *	1989-10-31	1999-07-06	Ophidian Pharmaceuticals, Inc.	Vaccine for clostridium botulinum neurotoxin
US5945098A (en) *	1990-02-01	1999-08-31	Baxter International Inc.	Stable intravenously-administrable immune globulin preparation
WO1991012718A1 (en) *	1990-03-01	1991-09-05	Agouron Pharmaceuticals, Inc.	Enhanced cryopreservation with thermal hysteresis peptide
US5401243A (en) *	1990-08-21	1995-03-28	Associated Synapse Biologics	Controlled administration of chemodenervating pharmaceuticals
KR920004485A (ko) *	1990-08-30	1992-03-27	다니엘 에이. 스콜라	친수성 중합체 및 이와 상이한 친수성 물질로 이루어진 신규 조성물
US5695956A (en) *	1990-11-26	1997-12-09	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Clostridium perfingens type a enterotoxin toxoid and methods of preparation and use as a vaccine and therapeutic agent
JP2916947B2 (ja) *	1990-11-28	1999-07-05	興和株式会社	Ｃｐｂ―ｉの安定化方法及び製剤組成物
US5704297A (en) *	1991-02-06	1998-01-06	The Dupont Merck Pharmaceutical Company	Dry powder composition of hydroxyethyl starch suitable for reconstitution
DK0590060T3 (da) *	1991-06-21	1998-05-11	Univ Cincinnati	Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
AU2309692A (en) *	1991-07-03	1993-02-11	Cryolife, Inc.	Method for stabilization of biomaterials
JPH0672891A (ja) *	1992-08-31	1994-03-15	Green Cross Corp:The	ヒト血清アルブミン含有製剤
JP3510886B2 (ja) *	1992-06-23	2004-03-29	ボツリヌムトキシンリサーチアソシエイトインコーポレイテッド	ボツリヌスｂ複合体を含有する医薬組成物
US5445817A (en) *	1992-08-21	1995-08-29	The United States Of America As Represented By The Department Of Health And Human Services	Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5728553A (en) *	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
JPH06192118A (ja) *	1992-09-28	1994-07-12	Wisconsin Alumni Res Found	ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法
US5466672A (en) *	1992-12-04	1995-11-14	Ophidian Pharmaceuticals, Inc.	Therapeutic use of clostridium difficile toxin A
JP3007785B2 (ja) *	1993-03-16	2000-02-07	旭化成工業株式会社	トロンボモジュリン組成物およびその変性防止方法
US5562907A (en) *	1993-05-14	1996-10-08	Arnon; Stephen S.	Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
EP0701455B1 (en) *	1993-06-04	2001-03-14	Biotime, Inc.	Plasma-like solution
US5437291A (en) *	1993-08-26	1995-08-01	Univ Johns Hopkins	Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
JP3684584B2 (ja) *	1993-12-17	2005-08-17	三菱ウェルファーマ株式会社	ヒト血清アルブミンの脱色方法
JP3533687B2 (ja) *	1993-12-17	2004-05-31	三菱ウェルファーマ株式会社	ヒト血清アルブミンの脱色方法
US5766605A (en) *	1994-04-15	1998-06-16	Mount Sinai School Of Medicine Of The City University Of New York	Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) *	1994-05-09	1997-09-23	Binder; William J.	Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
JP3066079B2 (ja) *	1994-05-09	2000-07-17	ビンダー，ウィリアム，ジェイ．	頭痛を低減する方法
JPH07308199A (ja) †	1994-05-18	1995-11-28	Green Cross Corp:The	ヒト血清アルブミンの製造方法
SK283026B6 (sk) *	1994-08-04	2003-02-04	Quadrant Holdings Cambridge Limited	Tuhý časticový prostriedok na terapeutické použitie a spôsob jeho prípravy
WO1996005222A1 (en) *	1994-08-08	1996-02-22	Wisconsin Alumni Research Foundation	Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) *	1994-10-13	1998-05-26	Wisconsin Alumni Research Foundation	Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) *	1994-10-13	1996-04-30	Wisconsin Alumni Research Foundation	Pharmaceutical composition of botulinum neurotoxin and method of preparation
DK0773788T3 (da) *	1995-06-06	2003-09-01	Allergan Inc	Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
US5919463A (en) *	1995-07-07	1999-07-06	Oravax, Inc.	Clostridium difficle toxins as mucosal adjuvants
JP3098401B2 (ja) *	1995-07-12	2000-10-16	株式会社エルティーティー研究所	経鼻投与用製剤
DE19538687A1 (de) *	1995-10-17	1997-04-24	Boehringer Mannheim Gmbh	Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
US5837265A (en) *	1996-03-08	1998-11-17	The Regents Of The University Of California	Chemically-modified clostridiatoxin with improved properties
US6150133A (en) *	1996-03-13	2000-11-21	Delta Biotechnology Limited	Fermentation control
US5721215A (en) *	1996-03-20	1998-02-24	Allergan	Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5908825A (en) *	1997-01-09	1999-06-01	University Of Maryland At Baltimore	Dosage composition for nasal delivery and method of use of the same
JPH10245400A (ja) *	1997-02-28	1998-09-14	Eiken Chem Co Ltd	トランスフェリンレセプターの安定化方法
JPH10251161A (ja) *	1997-03-11	1998-09-22	Green Cross Corp:The	浮腫治療効果増強剤
US6210683B1 (en) *	1997-09-05	2001-04-03	Merck & Co., Inc.	Stabilizers containing recombinant human serum albumin for live virus vaccines
US6051239A (en) *	1997-10-20	2000-04-18	Thomas Jefferson University	Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
PT917879E (pt) *	1997-11-22	2002-12-31	Roche Diagnostics Gmbh	Processo melhorado para estabilizacao de proteinas
US6346519B1 (en) *	1998-09-09	2002-02-12	Advanced Medical Instruments	Method and composition for treating arthritis
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
US6358917B1 (en) *	1999-08-24	2002-03-19	Jean D. A. Carruthers	Cosmetic use of botulinum toxin for treatment of downturned mouth
US6113915A (en) *	1999-10-12	2000-09-05	Allergan Sales, Inc.	Methods for treating pain
US6139845A (en) *	1999-12-07	2000-10-31	Allergan Sales, Inc.	Method for treating cancer with a neurotoxin
US6337075B1 (en) *	2000-01-11	2002-01-08	Allergan Sales, Inc.	Methods for treating diabetes
CA2478621C (en) *	2000-02-08	2006-11-21	Allergan, Inc.	Botulinum toxin pharmaceutical compositions
JP2003009897A (ja) *	2001-07-03	2003-01-14	Keiji Oguma	ボツリヌス毒素の分離・精製法
MXPA01011542A (es) *	2001-11-13	2003-05-22	Alcon Inc	Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.

2001
- 2001-02-05 CA CA002478621A patent/CA2478621C/en not_active Expired - Lifetime
- 2001-02-05 AT AT04029089T patent/ATE519494T1/de active
- 2001-02-05 AU AU3331501A patent/AU3331501A/xx active Pending
- 2001-02-05 EP EP03025104A patent/EP1398038B2/en not_active Expired - Lifetime
- 2001-02-05 ES ES01905436T patent/ES2237551T3/es not_active Expired - Lifetime
- 2001-02-05 DK DK03025104.5T patent/DK1398038T4/da active
- 2001-02-05 DK DK04029089.2T patent/DK1514556T3/da active
- 2001-02-05 NZ NZ530779A patent/NZ530779A/en not_active IP Right Cessation
- 2001-02-05 PT PT01905436T patent/PT1253932E/pt unknown
- 2001-02-05 DE DE60125986T patent/DE60125986T3/de not_active Expired - Lifetime
- 2001-02-05 PT PT03025104T patent/PT1398038E/pt unknown
- 2001-02-05 DE DE60110372T patent/DE60110372T2/de not_active Expired - Lifetime
- 2001-02-05 CA CA002400318A patent/CA2400318C/en not_active Expired - Fee Related
- 2001-02-05 DK DK01905436T patent/DK1253932T3/da active
- 2001-02-05 EP EP04029089A patent/EP1514556B1/en not_active Expired - Lifetime
- 2001-02-05 EP EP05006664A patent/EP1586329A1/en not_active Ceased
- 2001-02-05 CN CNB018046592A patent/CN1258379C/zh not_active Expired - Fee Related
- 2001-02-05 JP JP2001557580A patent/JP2003522154A/ja active Pending
- 2001-02-05 WO PCT/US2001/003641 patent/WO2001058472A2/en active Application Filing
- 2001-02-05 PT PT04029089T patent/PT1514556E/pt unknown
- 2001-02-05 EP EP01905436A patent/EP1253932B1/en not_active Expired - Lifetime
- 2001-02-05 ES ES04029089T patent/ES2368061T3/es not_active Expired - Lifetime
- 2001-02-05 AT AT01905436T patent/ATE293988T1/de active
- 2001-02-05 NZ NZ520201A patent/NZ520201A/en not_active IP Right Cessation
- 2001-02-05 ES ES03025104T patent/ES2275992T5/es not_active Expired - Lifetime
- 2001-02-05 AU AU2001233315A patent/AU2001233315B2/en not_active Ceased
- 2001-02-05 CA CA2494241A patent/CA2494241C/en not_active Expired - Fee Related
- 2001-02-05 MX MXPA02007519A patent/MXPA02007519A/es active IP Right Grant
- 2001-02-05 BR BR0108173-0A patent/BR0108173A/pt not_active IP Right Cessation
- 2001-02-05 CN CNB2004100117577A patent/CN1331532C/zh not_active Expired - Fee Related
- 2001-02-05 KR KR1020027010146A patent/KR100753765B1/ko not_active Expired - Lifetime
- 2001-02-06 TW TW095148526A patent/TWI317283B/zh not_active IP Right Cessation
- 2001-02-06 TW TW090102480A patent/TWI282739B/zh not_active IP Right Cessation
- 2001-02-08 AR ARP010100574A patent/AR027391A1/es not_active Application Discontinuation
2002
- 2002-01-14 US US10/047,058 patent/US20020064536A1/en not_active Abandoned
2004
- 2004-03-23 JP JP2004084590A patent/JP4118830B2/ja not_active Expired - Lifetime
2005
- 2005-03-18 JP JP2005079801A patent/JP2005179375A/ja active Pending
- 2005-07-05 JP JP2005196335A patent/JP2005336201A/ja not_active Withdrawn
2006
- 2006-03-14 KR KR1020060023656A patent/KR100665469B1/ko not_active Expired - Fee Related
- 2006-07-04 KR KR1020060062380A patent/KR100799400B1/ko not_active Expired - Lifetime
2007
- 2007-03-26 CY CY20071100420T patent/CY1108007T1/el unknown
- 2007-08-15 JP JP2007211802A patent/JP5080902B2/ja not_active Expired - Lifetime
2008
- 2008-04-25 US US12/109,486 patent/US20080213315A1/en not_active Abandoned
2011
- 2011-07-22 JP JP2011160451A patent/JP2011251988A/ja active Pending
- 2011-10-25 JP JP2011233808A patent/JP2012031194A/ja active Pending

Also Published As

Publication number	Publication date
JP2007332155A (ja)	2007-12-27
DE60125986T2 (de)	2007-10-18
CA2494241A1 (en)	2001-08-16
JP2004256545A (ja)	2004-09-16
DK1514556T3 (da)	2011-10-24
CN1398188A (zh)	2003-02-19
JP4118830B2 (ja)	2008-07-16
ATE519494T1 (de)	2011-08-15
CA2400318A1 (en)	2001-08-16
AR027391A1 (es)	2003-03-26
JP2005179375A (ja)	2005-07-07
AU3331501A (en)	2001-08-20
JP2012031194A (ja)	2012-02-16
CA2478621C (en)	2006-11-21
TW200711657A (en)	2007-04-01
CN1331532C (zh)	2007-08-15
AU2001233315B2 (en)	2004-07-08
CA2400318C (en)	2005-06-14
JP2005336201A (ja)	2005-12-08
ATE293988T1 (de)	2005-05-15
CN1616084A (zh)	2005-05-18
EP1398038B2 (en)	2011-01-26
JP5080902B2 (ja)	2012-11-21
JP2011251988A (ja)	2011-12-15
ES2275992T5 (es)	2011-05-18
EP1398038A1 (en)	2004-03-17
KR20060028475A (ko)	2006-03-29
PT1253932E (pt)	2005-07-29
PT1514556E (pt)	2011-09-08
EP1586329A1 (en)	2005-10-19
CA2478621A1 (en)	2001-08-16
JP2003522154A (ja)	2003-07-22
EP1514556B1 (en)	2011-08-10
DK1253932T3 (da)	2005-06-27
TWI282739B (en)	2007-06-21
KR100665469B1 (ko)	2007-01-04
DE60110372T2 (de)	2006-01-19
CA2494241C (en)	2011-06-14
ES2237551T3 (es)	2005-08-01
KR100799400B1 (ko)	2008-01-30
ES2275992T3 (es)	2007-06-16
EP1514556A1 (en)	2005-03-16
US20020064536A1 (en)	2002-05-30
MXPA02007519A (es)	2004-10-15
EP1253932B1 (en)	2005-04-27
DE60110372D1 (de)	2005-06-02
CN1258379C (zh)	2006-06-07
CY1108007T1 (el)	2013-09-04
NZ520201A (en)	2004-04-30
KR20020084115A (ko)	2002-11-04
US20080213315A1 (en)	2008-09-04
DK1398038T4 (da)	2011-03-28
EP1398038B1 (en)	2007-01-10
EP1253932A2 (en)	2002-11-06
TWI317283B (en)	2009-11-21
WO2001058472A2 (en)	2001-08-16
PT1398038E (pt)	2007-02-28
WO2001058472A3 (en)	2002-01-03
NZ530779A (en)	2004-08-27
KR100753765B1 (ko)	2007-08-31
KR20060090938A (ko)	2006-08-17
BR0108173A (pt)	2003-01-21
ES2368061T3 (es)	2011-11-14
DE60125986D1 (de)	2007-02-22
DE60125986T3 (de)	2011-07-28

Publication	Publication Date	Title
DK1398038T4 (da)	2011-03-28	Lægemidler med botulinustoxin
NO20071303L (no)	2001-07-27	Farmasoytiske preparater
ATE322251T1 (de)	2006-04-15	Neurotoxin implantat
DE60115698D1 (de)	2006-01-12	Medikamentenspender
DK1524266T3 (da)	2007-06-25	Farmaceutisk sammensætning
DE60138063D1 (de)	2009-05-07	Markenunabhängiger Ausrichtungssensor
EP1329217A4 (en)	2007-04-04	Solid preparations
ATE391531T1 (de)	2008-04-15	Schweisshemmende mittel
DE50114386D1 (de)	2008-11-20	Ng
DE60126089D1 (de)	2007-03-08	Verabreichungssystem
MXPA03001425A (es)	2003-06-06	Compuestos farmaceuticos.
DE60019901D1 (de)	2005-06-09	Rillenwalzvorrichtung
NO20030276D0 (no)	2003-01-20	Fremgangsmåte
DE50103344D1 (de)	2004-09-23	Loslager
DK1331972T3 (da)	2007-11-05	Farmaceutiske præparater
DE60103664D1 (de)	2004-07-08	Schwarzschulterklemmung
DE60100773D1 (de)	2003-10-23	Glycosphingolipid
DE50112183D1 (de)	2007-04-26	Walzenvorrichtung
DE60143209D1 (de)	2010-11-18	Zweiport-demodulationseinrichtung
IS6712A (is)	2003-02-11	Örmalað torsemíð
ATA4522000A (de)	2001-02-15	Sektionaltor
ATE327387T1 (de)	2006-06-15	Gleiseindeckung
DE60100451D1 (de)	2003-08-14	Neigungsgelenktes Rollgerät
ITRM20000220A1 (it)	2001-10-22	Cinnamilidenidrazide isonicotinica c15h13n3o
ITCH20000005U1 (it)	2001-01-16	Pista da biglia